share_log

Antibe Therapeutics Inc. to Post FY2023 Earnings of ($0.39) Per Share, Echelon Wealth Partners Forecasts (TSE:ATE)

Antibe Therapeutics Inc. to Post FY2023 Earnings of ($0.39) Per Share, Echelon Wealth Partners Forecasts (TSE:ATE)

安提贝治疗公司将公布2023财年每股收益(0.39美元)，Echelon Wealth Partners Forecast(TSE：ATE)
Defense World ·  2022/08/19 04:01

Antibe Therapeutics Inc. (TSE:ATE – Get Rating) – Echelon Wealth Partners decreased their FY2023 earnings per share (EPS) estimates for shares of Antibe Therapeutics in a research note issued to investors on Monday, August 15th. Echelon Wealth Partners analyst S. Quenneville now forecasts that the company will earn ($0.39) per share for the year, down from their prior forecast of ($0.38). The consensus estimate for Antibe Therapeutics' current full-year earnings is ($0.65) per share.

安提贝治疗公司(多伦多证券交易所股票代码：ATE-GET评级)--Echelon Wealth Partners在8月15日星期一发布给投资者的一份研究报告中下调了对安提贝治疗公司股票2023财年每股收益(EPS)的预期。Elhelon Wealth Partners分析师S.Quenneville现在预测，该公司今年的每股收益为0.39美元，低于此前预测的0.38美元。对安提贝治疗公司目前全年收益的普遍估计为每股0.65美元。

Get
到达
Antibe Therapeutics
安提贝治疗公司
alerts:
警报：

Separately, Brookline Capital Management restated a "buy" rating on shares of Antibe Therapeutics in a research note on Monday.

另外，Brookline Capital Management在周一的一份研究报告中重申了对安替比治疗公司股票的“买入”评级。

Antibe Therapeutics Stock Performance

安提贝治疗公司股票表现

TSE ATE opened at C$0.66 on Thursday. The company has a debt-to-equity ratio of 0.29, a current ratio of 13.07 and a quick ratio of 11.92. The business has a 50 day moving average price of C$0.62 and a 200 day moving average price of C$0.68. The company has a market capitalization of C$34.39 million and a P/E ratio of -1.23. Antibe Therapeutics has a 1-year low of C$0.56 and a 1-year high of C$1.30.
周四，Tse ATE开盘报0.66加元。该公司的债务权益比为0.29，流动比率为13.07，速动比率为11.92。该业务的50日移动均线价格为0.62加元，200日移动均线价格为0.68加元。该公司市值为3439万加元，市盈率为-1.23。安提贝治疗公司的一年低点为0.56加元，一年高位为1.30加元。

Antibe Therapeutics Company Profile

安提贝治疗公司简介

(Get Rating)

(获取评级)

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

安提贝治疗公司是一家生物技术公司，致力于在加拿大、欧洲、美国和国际上开发疼痛、炎症和再生医学领域的新型疗法和医疗设备。该公司的药物旨在防止非类固醇抗炎药造成的胃肠道损伤和出血。

Featured Stories

专题报道

  • If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
  • Is Sanofi A Buy, Despite Recent Stumbles?
  • Institutional Support For TJX Companies May Cap Gains
  • Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
  • BJ's Wholesale Club Pops, Will Costco Be Next?
  • 如果你讨厌超速摄像头，那么你会喜欢Verra Mobility Stock
  • 尽管赛诺菲最近跌跌撞撞，但它是买入的吗？
  • 对TJX公司的机构支持可能限制涨幅
  • 星巴克股票，品牌忠诚度足以成为购买理由吗
  • BJ‘s批发俱乐部流行音乐，Costco会是下一个吗？

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受《安提贝治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对安替比治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发